AKCA News and Press, Akcea Therapeutics Inc. From 06/17/20

BOSTON , June 17, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt , chief ex...

Akcea Therapeutics ( AKCA ) is a $1.5bn company with $421mn in cash reserves and very little debt . The company is a spin-off from the lipid pipeline of the much bigger Ionis Pharmaceuticals ( IONS ), which owns 76% of the outstanding AKCA stock. It has two approved drugs with a steady small ...

BOSTON , June 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei , Ph.D., has joined the company as Senior Vice President of Business Development & Corporate Strategy. In this...

BOSTON , June 8, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that AIFA, or The Italian Medicines Agency, has granted approval for the reimbursement of TEGSEDI® (inotersen) for the treatm...

Quick Take Avidity Biosciences ( RNA ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing treatments for diseases including various dystrophies and Pompe disease. RNA is a very early stage firm but has a sig...

TEGSEDI is first antisense oligonucleotide medicine available to patients in Portugal for at-home subcutaneous injection BOSTON , June 1, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the...

Ionis Pharmaceuticals (NASDAQ: IONS ) majority-owned affiliate Akcea Therapeutics (NASDAQ: AKCA ) announces the publication of long-term data from the NEURO-TTR study evaluating Tegsedi (inotersen) in patients with hereditary transthyretin (hATTR) amyloidosis with polyneuropathy. The resul...

Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) experienced sustained improvements in measures of neuropathic progression at 39 months of therapy,...

BOSTON , May 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and chief financial officer. In this role, Mr. Price wi...

TEGSEDI is the first antisense medicine available to patients in Spain for at-home subcutaneous injection Approval Issued by Ministry of Health of Spain Only Six Months After Submission BOSTON , May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-o...